Merck
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Machine Learning Cancer Prognostic Tool Identifies MYC Gain as Glioma Drug Resistance Marker
Premium
The open-source CELLO2 algorithm helped identify a subset of glioma patients at high risk for developing resistance to Merck's Temodar (temozolomide).
Alliance for Genomic Discovery Adds Major Biopharma Partners to Help Fund WGS-Based Biobank
Funding from AbbVie, Amgen, AstraZeneca, Bayer, and Merck will enable DeCode Genetics to sequence an additional 215,000 samples for the alliance.
Industry Groups Form European Coalition to Push for Better Comprehensive Genomic Profiling Access
A coalition of a trade group and drugmakers and diagnostics firms aims to share best practices and recommendations for better test reimbursement and uptake.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.